Oscar Goodman is an Oncology physician affiliated with Comprehensive Cancer Centers of Nevada. OpenAlex indexes 71 publications with 1,488 citations (h-index 18); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
9280 W Sunset Rd Ste 100
Las Vegas, NV 891484861
Telephone
702-952-1251Provider last certified this registry record 16 Oct 2025.
Clinical trials
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
35 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Bayer Healthcare Pharmaceuticals Inc.Program year202523 payments$26,852openpaymentsdata.cms.gov ↗
- AstraZeneca Pharmaceuticals LPProgram year202520 payments$21,805openpaymentsdata.cms.gov ↗
- Dendreon Pharmaceuticals LLCProgram year202519 payments$17,234openpaymentsdata.cms.gov ↗
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
61.2%PD-1 inhibitor59.9%Pembrolizumab52%Nivolumab48%Part B, office-administered≥40 patientsGonadotropin Releasing Hormone Receptor Agonist0.3%Leuprolide acetate100%Part B, office-administered≥45 patients+ 11 more classes in this area
Blood & clotting
20.5%Erythropoiesis-stimulating Agent20.3%Darbepoetin alfa100%Part B, office-administered≥19 patientsFactor Xa inhibitor0.1%Xarelto58%Eliquis43%Part D<11 patients+ 2 more classes in this area
Metabolism & gastrointestinal
10.7%Other antiemetics6.5%Fosaprepitant100%Part B, office-administered≥26 patientsSerotonin-3 Receptor Antagonist3.9%Granisetron hydrochloride83%Palonosetron hcl16%Ondansetron Odt1%Part D + Part B≥44 patients+ 7 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
Nicholas Vogelzang, MD
Comprehensive Cancer Centers of Nevada
Fadi Braiteh, MD
Comprehensive Cancer Centers of Nevada
Raul Meoz, MD
Comprehensive Cancer Centers of Nevada
Edwin Kingsley, MD
Comprehensive Cancer Centers of Nevada
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”